Psychedelic Alpha Bulletin 205: AbbVie targets Gilgamesh, U.S. psychedelic use rises, FDA moves to ban 7-OH-Kratom compound

Psychedelic Alpha Bulletin 205 compiles several psychedelic industry and policy signals, tying together corporate, clinical, and regulatory developments. The bulletin highlights AbbVie interest in Gilgamesh, framing ongoing investment and acquisition activity as major momentum for the psychedelic pipeline. It also reports that psychedelic use is increasing in the United States, presenting demand and adoption trends as part of the broader mainstreaming story. Finally, the bulletin covers a U.S. FDA regulatory move involving a kratom-related compound (7-OH), emphasizing tightening oversight and the downstream impact on consumer access and product definitions.